From NuGOwiki
The NuGOwiki Metabolite Database is a joint initiative of NuGO and HMDB
| Taxonomy Navigation Box; search by |
|
All Metabolites | Biochemical | Nutritional | Functional | Metabolic Pathways | Diseases | Phenotypes | Physiological Processes | Protein |
| Apolipoprotein C-III | |
|---|---|
| [[Image:{{{Image}}}|thumb|220px|2D structure for Apolipoprotein C-III]] | |
| Chemical Name | |
| Chemical Formula | |
| CAS Number | |
| Chemical Information | |
| Biochemical Taxonomy | |
| Functional Taxonomy | |
| Nutritional Taxonomy | |
| Metabolic Pathways | |
| Biofluid Location | |
| Tissue Location | |
| Normal Biofluid Concentrations | |
| Normal Tissue Concentrations | |
| Diseases / Conditions Related to Nutrition | |
| Other (Monogenic Disorders) | |
| Abnormal Biofluid Concentrations | |
| Abnormal Tissue Concentrations | |
| Physiological Processes | |
| Authors: | L. Pellis |
| Affiliations: | TNO, the Netherlands |
Contents |
Introduction
ApoCIII is synthesized predominantly in the liver and to a lesser degree in the intestine. It is present on VLDLs and chylomicron remnants; and to some extent on HDLs. ApoCIII is a cofactor for sphingomyelinase, an inhibitor of LPL and may activate LCAT. Individuals with a combined hereditary deficiency of both ApoAI and ApoCIII are predisposed to coronary heart disease.
Biological Function
ApoC-III interferes with lipoprotein particle clearance, but its principal role is as an inhibitor of lipolysis, both through the biochemical inhibition of lipoprotein lipase and by interfering with lipoprotein binding to the cell-surface glycosaminoglycan matrix where lipolytic enzymes and lipoprotein receptors reside.
Catabolism
Diseases / Conditions Related to Nutrition
Associated decreased protein/metabolite profile
Associated increased protein/metabolite profile
Other (Monogenic) Disorders
Nutritional Information
Drivers for biological variation